<DOC>
	<DOCNO>NCT02372513</DOCNO>
	<brief_summary>Cholesteryl Ester Storage Disease ( CESD ) autosomal recessive lysosomal storage disorder ( LSD ) cause mutation lysosomal acid lipase gene ( LIPA ) markedly reduce lysosomal acid lipase ( LAL ) activity , lead accumulation lipid , predominately cholesteryl ester triglyceride , various tissue cell type . In liver , accumulation lipid lead diffuse microvesicular steatosis , progress fibrosis ultimately , micronodular cirrhosis . Patients typically present hepatomegaly , liver dysfunction , hepatic failure type II hyperlipidemia . Although hepatosteatosis typical finding , liver biopsy diagnosis may misclassified non-alcoholic fatty liver disease , non-alcoholic steatohepatitis cryptogenic liver disease . Biopsy radiological finding consider diagnostic , help suspicion CESD . The definitive diagnosis base deficient LAL activity and/or LIPA gene mutation . CESD pan-ethnic , however , disease incidence unknown . The estimated incidence disease indicate CESD largely underdiagnosed especially European patient . Elevation serum transaminase , hepatomegaly early indication liver impairment . Therefore , CESD consider differential diagnosis liver disease unknown origin . To data , study evaluate frequency CESD child unexplained transaminase elevation and/or organomegaly and/or chronic liver disease . The aim prospective , multicenter cross-sectional study investigate frequency CESD child unexplained transaminase elevation and/or and/or chronic liver disease identify demographic clinical feature CESD .</brief_summary>
	<brief_title>National Lysosomal Acid Lipase Deficiency Study</brief_title>
	<detailed_description>Patients 3 month 18 year age time enrolment unexplained transaminase elevation ( serum alanine aminotransferase ( ALT ) level &gt; 1.5 time upper limit normal ) 3 month and/or unexplained hepatomegaly hepatosplenomegaly and/or obesity- unrelated hepatosteatosis and/or biopsy-proven cryptogenic fibrosis cirrhosis and/or liver transplantation cryptogenic cirrhosis include . Potential participant invite LAL enzyme analysis . Written inform consent obtain parent guardian participant time enrolment . Prospective retrospective data collect . Complete family medical history , physical examination previously exist laboratory finding record standard case report form 0.25 ml blood drawn LAL enzyme analysis . The blood obtain participant spotted filter paper , dry blood spot sample ( DBS ) prepare . Finally , dry blood spot sample send reference laboratory ( NHS Greater Glasgow Clyde , England ) LAL enzyme measurement within 1 week .</detailed_description>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Wolman Disease</mesh_term>
	<mesh_term>Cholesterol Ester Storage Disease</mesh_term>
	<criteria>1 . A male female 3 month 18 year age time enrolment 2 . Patients unexplained transaminase elevation ( serum ALT level &gt; 1.5 time upper limit normal ) 3 month 3 . Patients unexplained hepatomegaly hepatosplenomegaly 4 . Patients obesity unrelated hepatosteatosis 5 . Patients biopsyproven cryptogenic fibrosis cirrhosis 6 . Patients liver transplantation cryptogenic cirrhosis 1 . A male female &lt; 3 month &gt; 18 year old 2 . Patients obesity relate hepatosteatosis 3 . Patients druginduced hepatosteatosis ( aspirin , methotrexate , amiodarone , glucocorticoid , tamoxifen , 5fluorouracil , valproate , nucleoid revers transcriptase inhibitor ) 4 . Patients organomegaly transaminase elevation due infectious cause ( EBV , Brucella , cytomegalovirus , salmonella , malaria , leishmania etc ) , h√¶matooncological disease ( hemolytic anemia , leukemia , lymphoma , malign benign liver neoplasms ) , connective tissue disorder ( SLE , RA ) , cardiac vascular cause ( heart failure , pericarditis , BuddChiari syndrome , portal vein thrombosis ) obesity . 5 . Patient definitive diagnose chronic liver disease chronic viral hepatitis ( B , C hepatitis ) , autoimmune hepatitis , alpha1 antitrypsin deficiency , Wilson disease , metabolic disorder .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Cholesteryl Ester Storage Disease</keyword>
	<keyword>Children</keyword>
	<keyword>Liver disease</keyword>
</DOC>